---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-093263"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:34:48.086457+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics CEO resigns; Holger Weis appointed; audit committee shortfall triggers Nasdaq notice

## Summary
- Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
- Holger Weis appointed CEO July 2, 2025; $275,000 base salary; option for 130,000 shares at $5.06.
- Weis resigned from audit and compensation committees, causing non-compliance with Nasdaq Rule 5605(c); company intends to use 180-day grace period.
- Hogue entered consulting agreement at $250/hour for strategic advisory services.

## SEC filing metadata
- accession: 0000950170-25-093263
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/0000950170-25-093263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/tcrt-20250701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-093263
- JSON: https://secwatch.observer/filing/0000950170-25-093263.json
- Plain text: https://secwatch.observer/filing/0000950170-25-093263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.